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opment of treatments for rare diseases. This has resulted in 515
EU designations for orphan medicinal products in June 2008.
Many orphan drugs (ODs) receive market authorisation,
however there are problems regarding access and reimbursement.
This study compares OD policies and examines the reimburse-
ment of ODs across Europe. METHODS: Policies on ODs in
European countries for which sufﬁcient detail had been published
were examined. HTA websites were searched for assessments on
ODs and data extracted on the recommendations. RESULTS: In
some countries, including Sweden and The Netherlands, ODs
may be approved for reimbursement with minimal documenta-
tion of cost-effectiveness. However, many countries, including
England and Scotland do not have speciﬁc polices for the
appraisal and reimbursement of ODs. This results in many
patients across Europe who do not see any beneﬁt from the
orphan product legislation. By April 2008, 45 drugs with desig-
nated OD status had been given European marketing authorisa-
tion in 42 different indications. Thirty-seven submissions had
been assessed by the SMC by June 2008 according to the stan-
dard appraisal procedures, with 4 accepted for use, 13 accepted
for restricted use and 20 not recommended in NHS Scotland
(11%, 35% and 54%, respectively). This contrasts with previ-
ously published data on recommendations from the SMC; 30%
approved, 35% restricted, 36% not recommended (Karia et al.
2008). Furthermore, by June 2008, NICE had only assessed 2
OD indications, with 4 ODs currently undergoing assessment
and 3 proposed as topics for assessment. CONCLUSIONS: The
granting of market authorisation by the EMEA does not always
lead to reimbursement of a drug; patient access to ODs varies
across different European countries.
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OBJECTIVES: The quantity of research generated is increasing
yearly. It is of interest to determine the types of research being
published to assess the content of the current knowledge base.
Research can be categorized as randomized controlled trials
(RCTs), observational studies (OS), systematic reviews (SR), or
economic studies (ES). Our aim was to determine the proportion
of research being conducted in these categories and to assess the
relative proportions of each across time. METHODS: A citation
search was conducted in Medline on 18 June 2008. Search ﬁlters
for RCTs, OS, SR, and ES were implemented to provide an
estimate of research conducted in these categories for the years
1950–2007. The prevalence of each type of research was calcu-
lated and changes over time were analysed using logistic regres-
sions. RESULTS: The total probable citations retrieved were:
740 599 for RCTs, 1 217 246 for OS, 1 287 915 for SR, and
325 625 for ES. The proportion of research conducted for each
of these overall was 20.7%, 34.1%, 36.1%, and 9.1%, respec-
tively. From 1977 to 2007 there was a 12-fold increase in prob-
able RCTs, a 15-fold increase in both probable OS and SR, and
a 9-fold increase in probable ES. Logistic regression analysis
showed a signiﬁcant association between category and time
(p < 0.0005). CONCLUSIONS: The majority of research being
conducted appears to be focused on OS or reviews of the litera-
ture. In contrast, probable RCTs and ES, which are arguably the
most useful and rigorous forms of research, together consist of
less than one third of the research being conducted. Furthermore,
the increase in this research during the previous 30 years is lower
than that of OS and SR. It is possible that the focus on SR reﬂects
the growing recognition of the importance of this literature
searching technique.
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OBJECTIVES: We aim to investigate uncontrolled associations
between HRQOL and health services utilization among primary
care patients in mainland China. METHODS: A retrospective
cross-sectional design was carried out among patients consulting
in primary care in mainland China. Health services utilization
was measured by the number of monthly outpatient consultation
and the annual hospitalization rate. HRQOL was measured by
either electronic or paper version of the Chinese SF-36. The
clustered model was adapted to calculate the independent con-
tributions from scores of the SF-36 subscales. A total of 733 valid
subjects were eventually recruited for this study. RESULTS: The
score of MH has a negative association with the number of
monthly outpatient consultation and its independent contribu-
tion explained within the clustered model was 7.0%, whereas
both the score of GH and PF have negative associations with the
annual hospitalization rate and the independent contributions
from GH and PF was a total of 22.2%. CONCLUSIONS: In
summary, this was the ﬁrst study verifying that scores of the
SF-36 subscales have negative associations with outpatient and
inpatient consultation among primary care patients in mainland
China.
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OBJECTIVES: As Medicare Part D results in de facto centraliza-
tion of buying power in the US, we hypothesized that NICE
HTA’s would increasingly inﬂuence the US market. The primary
objective is to determine whether major ﬁndings of Health Tech-
nology Appraisals (HTAs) by the National Institute for Clinical
Excellence (NICE; UK) impacted US trends in prescription
volume, retail price and out-of-pocket costs of statins and of six
therapeutic classes deemed medically necessary for Medicare
beneﬁciaries. As a point of reference, we sought to investigate the
same market factors in relation to the index date of Medicare
Part D introduction. METHODS: The two most prescribed
statins (atorvastatin, simvastatin), anticonvulsants (clonazepam,
gabapentin), antidepressants (escitalopram, ﬂuoxetine), oral
antineoplastics (capecitabine, imatinib), antipsychotics (quetiap-
ine, risperidone), immunosuppressants (azathioprine, mycophe-
nolate), and antiretrovirals (emtricitabine/tenofovir, ritonavir)
were selected based on total prescriptions (TRx). TRx, average
retail price (ARP) and average out-of-pocket costs (OPC) per
prescription were collected quarterly for 2005–2008. For six
related HTAs conducted by NICE and the implementation of
Medicare Part D, TRx, ARP and OPC were analyzed for the
same number of quarters before and after the index event.
Parameters were collected using Verispan’s VONA and VOPA
databases. Statistical analyses were performed using one-way
ANOVA. RESULTS: From 2005 to 2008, 7 of the 14 drugs
analyzed were directly or indirectly covered by a NICE HTA.
Two HTAs were correlated with a signiﬁcant increase in TRx,
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